Metastatic Colon Cancer
Conditions
Brief summary
This clinical study will investigate the utility of PET imaging with \[89Zr\]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.
Interventions
DRUG[89Zr]Panitumumab PET-MRI
All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
Sponsors
University of Alabama at Birmingham
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Be at least 19 years of age. * Diagnosis of colon cancer * Scheduled to undergo surgical resection
Exclusion criteria
* Inability to provide informed consent * Pregnancy * Inability to lie still for the imaging study * Weight over 350 lbs., due to the scanner bore size * Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos) * Inability to receive Omnipaque (iohexol) iodinated contrast * Inability to receive glucagon * Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent * Allergy to contrast imaging agents * Finding or suspicion of distant metastases on CT
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Image Quality | 12 months | Diagnostic image quality of \[89Zr\]Panitumumab PET imaging in patients with newly diagnosed colon cancer with nodal involvement. Standardized Uptake Values (SUVs) will be measured. |
Outcome results
None listed